Answers are grounded in this paper and cite their sources.
Bispecific antibodies (BsAbs) are used for relapsed or refractory multiple myeloma (RRMM), but infectious complications remain an important concern. We estimated the reported proportion of all-grade and grade ≥3 infections during teclistamab, talquetamab, and elranatamab treatment.A systematic literature review was conducted with Pubmed to extract data which, included the number of patients, grade ≥ 3 infectious adverse events, and non-grade ≥ 3 infectious adverse events. Analyses were conducted using R software and the meta package. A random effect model was utilized.Eight studies (6 RCTs, 2 retrospective studies) involving 946 patients (teclistamab: 394, talquetamab: 374, elranatamab: 178) were analyzed. Pooled proportion (PP) for teclistamab was 0.517 [95% CI, 0.183-0.837], and grade ≥ 3 was 0.233 [95% CI, 0.058-0.598]. The talquetamab group had a PP of 0.636 [95% CI, 0.305-0.874], and grade ≥ 3 were 0.201 [95% CI, 0.110-0.339], with COVID-19 & pneumonia most reported. For elranatamab, the PP was 0.714 [95% CI, 0.397-0.904], with grade ≥ 3 infections at 0.344 [95% CI, 0.015-0.948]. Common infections were adenovirus, CMV, COVID-19, and pneumocystis jirovecii. Table 2 shows consistently reported AEs amongst the three bispecific antibodies for comparability.Infections were frequently reported, but substantial heterogeneity limits the precision and generalizability of a single pooled estimate. Consistent outcome definitions and follow-up are needed.
No takes yet. Share an insight, caveat, or question.
Shah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: